Tokyo, July 12, 2006 (JCN) - Takeda Pharmaceutical has signed a licensing agreement with Galaxy Biotech for HuL2G7, an anti-Hepatocyte Growth Factor (HGF) monoclonal antibody developed by Galaxy Biotech. Under the agreement announced July 10, Takeda Pharmaceutical will licensed to exclusively develop, manufacture, and sell HuL2G7 worldwide. Takeda Pharmaceutical will make an upfront payment of $2 million, milestone payments on future development and royalties on product sales.